Array BioPharma Inc

Most Recent

  • uploads///AdobeStock_
    Earnings Report

    Amarin’s Q2 Earnings and Robust 2019 Outlook

    Amarin Corporation (AMRN) reported its Q2 2019 earnings yesterday. Here’s how the stock, investors, and peer pharma stocks reacted.

    By Sushree Mohanty
  • uploads///entrepreneur _
    Company & Industry Overviews

    How PFE’s and BMY’s EPS Trends Compare

    In fiscal 2019, Pfizer (PFE) expects its adjusted diluted EPS to fall 4.0% YoY (year-over-year) to $2.83–$2.93.

    By Margaret Patrick
  • uploads///cells _
    Company & Industry Overviews

    An Overview of Array BioPharma Stock

    Array BioPharma generated total revenue of $56.91 million in the first quarter of fiscal 2019.

    By Kenneth Smith
  • uploads///capsule _
    Company & Industry Overviews

    How Analysts View Amicus Therapeutics in September

    Amicus Therapeutics (FOLD) plans to start the pivotal trial for AT-GAA in the second half of 2018.

    By Daniel Collins
  • uploads///puzzle _
    Company & Industry Overviews

    NovoCure Stock Rose after Positive Results from Clinical Trial

    On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40.

    By Daniel Collins
  • uploads///puzzle _
    Earnings Report

    What Analysts Recommend for Array BioPharma Stock

    As of August 15, analysts’ target price for ARRY is $23.57, which implies a ~71.7% return over the next 12 months based on the stock’s August 14 price of $13.73.

    By Sarah Collins
  • uploads///SALES ESTIMATES
    Earnings Report

    Array BioPharma Missed Sales Estimates for Q4 2018

    Array BioPharma (ARRY) reported its Q4 2018 and fiscal 2018 earnings results August 14. Its sales rose by ~4.9% YoY (year-over-year) to $35.4 million, missing analysts’ estimate of $38.7 million.

    By Sarah Collins
  • uploads///dna _
    Company & Industry Overviews

    Gauging Analysts’ Ratings for ArQule Stock in July

    ArQule (ARQL) stock has risen from a low of $5.53 on July 5 to $6.86 on July 6. It closed 20.11% higher at $6.81 on July 6.

    By Kenneth Smith
  • uploads///ecg electrocardiogram stethoscope
    Company & Industry Overviews

    Array BioPharma: Why Wall Street Analysts Are Positive

    Of the eight analysts tracking Array BioPharma in June, three recommended a “strong buy,” while five recommended a “buy.”

    By Daniel Collins
  • uploads///ARRY Revenue Trend
    Company & Industry Overviews

    Array BioPharma’s Financial Performance

    The total revenues of Array BioPharma (ARRY) decreased from $39.2 million in 1Q17 to $29.7 million in 1Q18.

    By Kenneth Smith
  • uploads///ARRY
    Company & Industry Overviews

    Array BioPharma’s ARRY-382 and ARRY-797

    Array BioPharma (ARRY) completed its Phase 1b clinical trial of its investigational drug candidate ARRY-382 in combination with Merck’s (MRK) Keytruda for advanced tumor indications.

    By Kenneth Smith
  • uploads///ARRY
    Company & Industry Overviews

    Array BioPharma’s Promising Drug for Colorectal Cancer

    On January 22, 2018, Array BioPharma announced data from the BEACON CRC trial, which showed a median progression-survival rate of eight months and an overall response rate of 48%.

    By Kenneth Smith
  • uploads///ARRY binimetinib and encorafenib
    Company & Industry Overviews

    An In-Depth Look at Array BioPharma’s Pipeline of Drugs

    In March 2015, Array BioPharma (ARRY) got the development and commercialization rights for binimetinib and encorafenib under asset transfer agreements with Novartis (NVS).

    By Kenneth Smith
  • uploads///ARRY Analysts reco
    Company & Industry Overviews

    Analyst Ratings for Array BioPharma and Peers in January 2018

    Of the nine analysts covering Array BioPharma (ARRY) in January 2018, eight have given the stock a “buy” or higher rating, and one has given it a “hold.”

    By Kenneth Smith
  • uploads///RDUS Revenue Growth
    Company & Industry Overviews

    Taking Stock of Radius Health’s Financial Performance

    In 3Q17, Radius Health (RDUS) generated revenue of $13.4 million. Of this revenue, $3.4 million came from product revenue, which comprises Tymlos sales and licensing revenue.

    By Kenneth Smith
  • uploads///Elacestrant market opportunity
    Company & Industry Overviews

    Taking Stock of Radius Health’s Licensing Agreements

    The market has responded very positively to Radius Health’s recent performance. In the past month, Radius stock has generated a 28% return for its shareholders.

    By Kenneth Smith
  • uploads///RDUS Analysts Reco
    Company & Industry Overviews

    Analysts’ Ratings for Radius Health and Its Peers in January

    In April 2017, Radius received FDA approval for its first commercial product, Tymlos. Tymlos was approved for the treatment of postmenopausal women with osteoporosis at a high risk for fracture.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.